Popularized in films like Limitless, legal smart drugs called Nootropics are becoming more and more prevalent in board rooms and on Wall Street.Keep reading »
Head of the Asia portfolio is said to be on the way out.
From the mailbag:
“Carl Huttenlocher, Highbridge MD and Head of Asia and member of the investment committee of Highbridge is leaving the firm. Carl has been with Highbridge since 2001. Really unusual and strange as Carl spent most of 2010 raising assets for his Asia fund and firmly committed to clients that he plans on staying with Highbridge. His fund is currently closed due to capacity. Seems that this will be a huge blow to Highbridge as Carl manages 2 billion usd in assets for the Asia fund and significant portion of Highbridge’s 10 bililon usd multistrategy fund. He is the key man risk for the Asia fund so clients may not be pleased.
Also seen in the Four Seasons hotel lobby in Hong Kong– CEO Glenn Dubin and COO Todd Builione…coincidence?”